[PULMONARY SYPHILIS IN PSEUDO-TUBERCULOTIC FORM (APROPOS OF A CASE SHOWING A RADIOLOGIC CURE)].

R. Voog,H. Dufour,L. Grandmaison

Abstract:

What problem does this paper attempt to address?

Monochromatic light sources in testing image intensifier tubes

K. Chrzanowski,omiej Radzik

Abstract:Military standards and literature sources recommend use of polychromatic light source of 2856K color temperature in testing image intensifier tubes. Tungsten halogen bulbs are standard sources of radiation used in commercially available test stations. However, there are two main disadvantages of tungsten bulbs: short life time and temporal changes of both light power and light spectrum. Application of monochromatic semiconductor sources in testing of image intensifiers as possible alternative of halogen bulbs is analyzed in this paper. It is shown that, if calibrated properly, monochromatic semiconductor sources can be used in stations for testing image intensifier tubes. Military standards require use of polychromatic light sources of 2856K color temperature in testing image intensifier tubes[1.a.i.[1]-1.a.i.[6]]. Tungsten halogen bulbs have been standard sources of radiation used in commercially available test stations for last few decades in testing image intensifier tubes [1.a.i.[7],1.a.i.[8]]. However, tungsten halogen bulbs have several significant limitations. First, they are not stable and emitted flux varies significantly in time. Second, they are characterized by short life time. Third, due to significant temporal inertia it is necessary to use mechanical shutters to enable tests of temporal characteristics of image intensifier tubes (II tubes). Sensitivity of image intensifier tubes depends significantly on wavelength. Therefore, illumination of the photocathode with 2856K color temperature light is not equivalent to illumination with monochromatic light of the same radiation power. However, let us analyze if properly calibrated monochromatic sources can replace 2856K color temperature halogen bulbs in test equipment to be used for testing image intensifier tubes and if accurate measurement of photometric parameters of II tubes is still possible. Quantitative relationships between input illuminance and output luminance is measured during the photometric tests of II tubes. The MIL standards state very precisely the necessary illuminance levels of 2856K color radiation to be used during measurement of photometric parameters of II tubes. The conversion coefficient between the illuminance level of 2856K light and the equivalent illuminance level of monochromatic light depends on spectral sensitivity curve of the tested tube that can vary with different tubes. Therefore we should use different conversion coefficients in order to calibrate properly the monochromatic source used during tests of tubes of different spectral sensitivity. * E-mail: kch@inframet.pl This feature is a significant drawback of semiconductor light sources but still in case of testing large number of II tubes of the same spectral sensitivity such monochromatic sources should be an interesting alternative of typical halogen bulbs. Here we will analyze possible application of monochromatic semiconductor sources (LED diodes) in testing of image intensifier tubes. These monochromatic sources are much more stable, are characterized by negligible temporal inertia and do not cause polychromatic aberration. Such sources are used sometimes in commercially available stations for testing II tubes [1.a.i.[7],1.a.i.[8]]. However, so far their applications have been limited to use in measurements of imaging parameters (resolution, MTF, image quality etc) of II tubes when, according to MIL standards, requirements on accuracy of illumination level are low. Here we are to investigate if it is possible to use semiconductor light sources in testing photometric parameters of II tubes (luminous sensitivity, luminance gain, etc) when requirements on accuracy of illumination level are high. In order to calibrate properly monochromatic source to be used instead of standard polychromatic light sources we will need an instrument that is sensitive to both polychromatic and monochromatic light. Let us make an assumption that we will use typical illuminance meters of spectral characteristics identical as spectral characteristics of humans eye as the sensing instrument of both polychromatic and monochromatic illumination at tube photocathode plane. The illuminace meters of sensitivity over 1 mlx are relatively low cost meters available at photometric laboratories. Next, let as assume that we will use a monochromatic source emitting light in the spectral range where both the tested II tubes and the illuminance meters are sensitive: from about 0.5 μm to 0.65μm. Krzysztof Chrzanowski, *1,2 Tomasz Raźniewski, Bartłomiej Radzik Military University of Technology, 2 Kaliski str., 00-908 Warsaw, Poland, Inframet, Graniczna 24, Kwirynow, 05-082 Stare Babice, Poland Received April 28, 2009; accepted June 29, 2009; published June 30, 2009 http://www.photonics.pl/PLP © 2009 Photonics Society of Poland PHOTONICS LETTERS OF POLAND, VOL. 1 (2), 79-81 (2009) 80 Now, let us analyse a situation when the photocathode of the image intensifier tube was illuminated using polychromatic 2856 K light and the illuminance meter recorded illuminance level Ep, and when the photocathode of the image intensifier tube was illuminated using monochromatic light the illuminance meter recorded illuminance level Em. Let us find what is the relationship between Ep and Em necessary to achieve situation when both light sources generate the same luminance level at the screen of the illuminated II tube. The light coming to the photocathode represent a certain stimulus that is measured by the illuminance meter in photometric units perfectly suitable for humans eye. Here however, let us analyse a case when the receptor of this stimulus is not human eye but image intensifier tube of significantly different spectral curve. If we use a light meter of spectral curve identical as tube curve then the corrected indication of the illuminace meter illuminated using polychromatic light Ep(cor) would be
Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Shangshi Zhang,Dongjun Dai,Xian Wang,Hongyan Zhu,Hongchuan Jin,Ruochi Zhao,Liting Jiang,Qi Lu,Fengying Yi,Xiangxiang Wan,Hanbin Cui

DOI: https://doi.org/10.1186/s12872-016-0250-2

IF: 2.174

2016-01-01

BMC Cardiovascular Disorders

Abstract:Background Recent studies have shown Growth differentiation factor–15 (GDF-15) that is a member of the transforming growth factor β (TGF-β) superfamily might be a potential predictive cytokine for the prognosis of Acute coronary syndrome (ACS). However, there are discrepancies in these studies. Methods Publication searches of the PubMed/Medline and EMBASE databases were performed without any time or ethnicity restrictions. The inclusion and exclusion criteria, when clear, were addressed. Random effects models were used for all analyses. Publication bias was tested using funnel plots and the Egger test. Results We identified eight eligible studies that provided mortality data. Five of these studies provided recurrent myocardial infarction (MI) data. The maximal duration of follow-up ranged from 6 months to 6 years. A significant association was found between the patients with the highest and lowest GDF-15 levels (overall analyses) in terms of mortality ( p < 0.00001; RR = 6.08; 95 % CI = 4.79–7.71) and recurrent MI ( p < 0.00001; RR = 1.76; 95 % CI = 1.49–2.07). We also found significant associations between the subgroup analyses stratified by ACS types, cutoff points and follow-up durations ( p < 0.001). The combined hazard ratio was high for GDF-15 to ACS (HR = 1.656, 95 % CI = 1.467–1.871). Conclusion High plasma GDF-15 levels are associated with an increased risk of mortality and recurrent MI in patients with ACS.
Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.

Ji Hao,Iokfai Cheang,Li Zhang,Kai Wang,Hui-Min Wang,Qian-Yun Wu,Yan-Li Zhou,Fang Zhou,Dong-Jie Xu,Hai-Feng Zhang,Wen-Ming Yao,Xin-Li Li

DOI: https://doi.org/10.1097/CM9.0000000000000449

IF: 6.133

2019-01-01

Chinese Medical Journal

Abstract:BACKGROUND:Clinical assessment and treatment guidance for heart failure depends on a variety of biomarkers. The objective of this study was to investigate the prognostic predictive value of growth differentiation factor-15 (GDF-15) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in assessing hospitalized patients with acute heart failure (AHF). METHODS:In total, 260 patients who were admitted for AHF in the First Affiliated Hospital of Nanjing Medical University were enrolled from April 2012 to May 2016. Medical history and blood samples were collected within 24 h after the admission. The primary endpoint was the all-cause mortality within 1 year. The patients were divided into survival group and death group based on the endpoint. With established mortality risk factors and serum GDF-15 level, receiver-operator characteristic (ROC) analyses were performed. Cox regression analyses were used to further analyze the combination values of NT-proBNP and GDF-15. RESULTS:Baseline GDF-15 and NT-proBNP were significantly higher amongst deceased than those in survivors (P < 0.001). In ROC analyses, area under curve (AUC) for GDF-15 to predict 1-year mortality was 0.707 (95% confidence interval [CI]: 0.648-0.762, P < 0.001), and for NT-proBNP was 0.682 (95% CI: 0.622-0.738, P < 0.001). No statistically significant difference was found between the two markers (P = 0.650). Based on the optimal cut-offs (GDF-15: 4526.0 ng/L; NT-proBNP: 1978.0 ng/L), the combination of GDF-15 and NT-proBNP increased AUC for 1-year mortality prediction (AUC = 0.743, 95% CI: 0.685-0.795, P < 0.001). CONCLUSIONS:GDF-15, as a prognostic marker in patients with AHF, is not inferior to NT-proBNP. Combining the two markers could provide an early recognition of high-risk patients and improve the prediction values of AHF long-term prognosis. CLINICAL TRIAL REGISTRATION:ChiCTR-ONC-12001944, http://www.chictr.org.cn.
Identification of Growth Differentiation Factor-15 as An Early Predictive Biomarker for Metabolic Dysfunction-Associated Steatohepatitis: A Nested Case-control Study of UK Biobank Proteomic Data

Hao Wang,Xiaoqian Xu,Yameng Sun,Hong You,Jidong Jia,You-Wen He,Yuanyuan Kong

DOI: https://doi.org/10.1101/2024.09.12.612665

2024-09-25

Abstract:Background & Aims: The lack of non-invasive biomarkers for the early prediction of patients with metabolic dysfunction-associated steatohepatitis (MASH) is a major challenge for timely intervention. This study aims to determine the predictive capability for MASH long before its diagnosis by using six previously identified diagnostic biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) with proteomic data from the UK Biobank. Methods: A nested case-control study comprising of a MASH group and three ageand sex-matched controls groups (metabolic dysfunction-associated steatosis, viral hepatitis, and normal liver controls) were conducted. Olink proteomics, anthropometric and biochemical data at baseline levels were obtained from the UK Biobank. The baseline levels of CDCP1, FABP4, FGF21, GDF15, IL-6 and THBS2 were analyzed prospectively to determine their predictive accuracy for subsequent diagnosis with a mean lag time of over 10 years. Results: At baseline, GDF15 demonstrated the best performance for predicting MASH occurrence at 5 and 10 years later, with an AUC of 0.90 at 5 years and 0.86 at 10 years. A predictive model based on four biomarkers (GDF15, FGF21, IL-6, and THBS2) showed AUCs of 0.88 at both 5 and 10 years. Furthermore, a protein-clinical model that included these four circulating protein biomarkers along with three clinical factors (BMI, ALT and TC) yielded AUCs of 0.92 at 5 years and 0.89 at 10 years. Conclusion: GDF15 at baseline levels outperformed other individual circulating protein biomarkers for the early prediction of MASH. Our data suggest that GDF15 and the GDF15-based model may be used as easy-to-implement tools to identify patients with high risk of developing MASH at a mean lag time of over 10 years.

Molecular Biology
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease

Grazia Pennisi,Rosaria Maria Pipitone,Marco Enea,Antonio De Vincentis,Salvatore Battaglia,Vito Di Marco,Vincenzo Di Martino,Federica Spatola,Federica Tavaglione,Umberto Vespasiani-Gentilucci,Rossella Zito,Stefano Romeo,Calogero Cammà,Antonio Craxì,Stefania Grimaudo,Salvatore Petta

DOI: https://doi.org/10.1002/hep4.1877

Abstract:Nonalcoholic fatty liver disease (NAFLD) is an emerging cause of liver-related events (LREs). Here, we have assessed the ability of a composite score based on clinical features, metabolic comorbidities, and genetic variants to predict LREs. A total of 546 consecutive patients with NAFLD were recruited and stratified according to the fibrosis-4 (FIB-4) index. LREs were defined as occurrence of hepatocellular carcinoma or hepatic decompensation. Cox regression multivariate analysis was used to identify baseline variables associated with LREs. The UK Biobank was used as the validation cohort, and severe liver disease (incidence of cirrhosis, decompensated liver disease, hepatocellular carcinoma, and/or liver transplantation) was used as the outcome. LREs were experienced by 58 patients, only one of whom was in the cohort of patients with a FIB-4 score < 1.3. Multivariate Cox regression analysis of 229 patients with a FIB-4 score ≥ 1.3 highlighted clinical variables independently associated with the development of LREs, including older age, low platelet count, low albumin, low high-density lipoprotein cholesterol, certain genetic factors, and interactions between genetic factors and sex or diabetes. The area under the curve (AUC) for the model was 0.87 at 1, 3, and 5 years. Our novel Genetic and Metabolic Staging (GEMS) scoring system was derived from the Cox model linear predictor, ranked from 0 to 10, and categorized into five classes (0-5, 5-6, 6-7, 7-8, and 8-10). The risk of LREs increased from 4% in patients in the best class (GEMS score 0-5) to 91% in the worst (GEMS score 8-10). GEMS score was associated with incident severe liver disease in the study population (hazard ratio, 1.56; 95% confidence interval, 1.48-1.65; P < 0.001) as well as in the UK Biobank cohort where AUCs for prediction of severe liver disease at 1, 3, and 5 years were 0.70, 0.69, and 0.67, respectively. Conclusion: The novel GEMS scoring system has an adequate ability to predict the outcome of patients with NAFLD.
Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease

Jae Seung Chang,Jhii-Hyun Ahn,Moon Young Kim,Kyu-Sang Park

DOI: https://doi.org/10.1038/s41598-024-77719-6

IF: 4.6

2024-11-13

Scientific Reports

Abstract:Mitochondrial dysfunction with oxidative stress contributes to metabolic dysfunction-associated steatotic liver disease (MASLD) progression. We aimed to evaluate the fibrosis predictive efficacy of a novel non-invasive diagnostic panel using metabolic stress biomarkers. From a population-based general cohort, 144 subjects with MASLD were recruited in the development group and underwent magnetic resonance imaging-based liver examinations, anthropometric and laboratory tests. As an external validation group, 41 patients enrolled in a biopsy-evaluated MASLD cohort participated in this study. Liver fat content and stiffness were measured by magnetic resonance (MR) imaging-proton density fat fraction and MR elastography (MRE), respectively. Serologic stress biomarkers were quantitated by ELISA. Multivariate regression showed that waist-to-height ratio, growth differentiation factor-15 (GDF15), γ-glutamyltransferase, decorin, and alkaline-phosphatase were independent predictors of hepatic fibrosis (rank-ordered by Wald). The area under receiver-operator characteristics curve [AUROC (95% CI)) of the metabolic stress index for fibrosis (MSI-F) was 0.912 (0.85‒0.98) and 0.977 (0.92‒1.00) in development and validation groups, respectively. MSI-F also had better diagnostic accuracy (82.6‒92.4%) than other fibrosis indices in the both study cohorts. MSI-F consistently differentiated fibrosis severities across cohorts of MRE-evaluated general population and biopsy-proven patients with MASLD, while other indices showed no or less discrimination. MSI-F, as a novel non-invasive index based on a stress-stimulated protective hormone GDF15 and decorin, effectively predicted hepatic fibrosis. Furthermore, MSI-F may serve as pre-screening tool to increase the population that could be excluded from further evaluation, reducing unnecessary invasive investigations more effectively than other indices.

multidisciplinary sciences
Maf-5 Predicts Liver Fibrosis Risk And Outcome In The General Population With Metabolic Dysfunction

Laurens A van Kleef,Sven M Francque,Jhon E Prieto-Ortiz,Milan J Sonneveld,Carlos B Sanchez-Luque,Robin G Prieto-Ortiz,Wilhelmus J Kwanten,Luisa Vonghia,An Verrijken,Christophe De Block,Zouhir Gadi,Harry L A Janssen,Robert J de Knegt,Willem P Brouwer,Laurens A. van Kleef,Sven M. Francque,Jhon E. Prieto-Ortiz,Milan J. Sonneveld,Carlos B. Sanchez-Luque,Robin G. Prieto-Ortiz,Wilhelmus J. Kwanten,Harry L.A. Janssen,Robert J. de Knegt,Willem P. Brouwer

DOI: https://doi.org/10.1053/j.gastro.2024.03.017

IF: 29.4

2024-03-21

Gastroenterology

Abstract:Background & aims There is an unmet need for non-invasive tests to improve case-finding and aid primary care professionals in referring patients at high risk of liver disease. Methods A metabolic dysfunction-associated fibrosis (MAF-5) score was developed and externally validated in a total of 21,797 individuals with metabolic dysfunction, in population-based (NHANES2017-2020, NHANESIII, Rotterdam Study) as well as hospital-based cohorts (from Antwerp and Bogota). Fibrosis was defined as liver stiffness (LSM)≥8.0kPa. Diagnostic accuracy was compared to FIB-4, NFS and SAFE. MAF-5 was externally validated with LSM≥8.0kPa, with shear-wave elastography (SWE≥7.5 kPa) and biopsy-proven steatotic liver disease according to METAVIR and NASH-CRN scores, and was tested for prognostic performance (all-cause mortality). Results The MAF-5 score comprised waist circumference, BMI, diabetes, AST and platelets. With this score, 60.9% was predicted at low, 14.1% at intermediate and 24.9% at high risk of fibrosis. The observed prevalence was 3.3%, 7.9% and 28.1%, respectively. The AUROC of MAF-5 (0.81) was significantly higher than FIB-4 (0.61), and outperformed the FIB-4 among the young (NPV 99% [AUC 0.86] versus 94% [AUC 0.51]) and elderly (NPV 94% [AUC 0.75] versus 88% [AUC 0.55]). MAF-5 showed excellent performance to detect LSM≥12kPa (AUC 0.86 training, AUC 0.85 validation) and good performance in detecting liver stiffness and biopsy-proven liver fibrosis among the external validation cohorts. MAF-5 score>1 was associated with increased risk of all-cause mortality in (un)adjusted models (aHR:1.59, 95%CI:1.47–1.73). Conclusion The MAF-5 score is a validated, age-independent, inexpensive referral tool to identify individuals at high risk of liver fibrosis and all-cause mortality in primary care populations, using simple variables.

gastroenterology & hepatology
Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction

Ana Belen Mendez Fernandez,Andreu Ferrero-Gregori,Alvaro Garcia-Osuna,Sonia Mirabet-Perez,Maria Jose Pirla-Buxo,Juan Cinca-Cuscullola,Jordi Ordonez-Llanos,Eulàlia Roig Minguell

DOI: https://doi.org/10.1002/ehf2.12621

Abstract:Aims: The prognostic value of biomarkers in patients with heart failure (HF) and mid-range (HFmrEF) or preserved ejection fraction (HFpEF) has not been widely addressed. The aim of this study was to assess whether the prognostic value of growth differentiation factor 15 (GDF-15) is superior to that of N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with HFmrEF or HFpEF. Methods and results: Heart failure patients with either HFpEF or HFmrEF were included in the study. During their first visit to the HF unit, serum samples were obtained and stored for later assessment of GDF-15 and NT-proBNP concentrations. Patients were followed up by the HF unit. The main endpoint was all-cause mortality. A total of 311 patients, 90 (29%) HFmrEF and 221 (71%) HFpEF, were included. Mean age was 72 ± 13 years, and 136 (44%) were women. No differences were found in GDF-15 or NT-proBNP concentrations between both HF groups. During a median follow-up of 15 months (Q1-Q3: 9-30 months), 98 patients (32%) died, most (71%) of cardiovascular causes. Patients who died had higher median concentrations of GDF-15 (4085 vs. 2270 ng/L, P < 0.0001) and NT-proBNP (1984 vs. 1095 ng/L, P < 0.0001). A Cox multivariable model identified New York Heart Association Functional Class III (P = 0.04), systolic blood pressure (P = 0.01), left atrial diameter (P = 0.03), age >65 years (P < 0.0001), and GDF-15 concentrations (P = 0.01) but not NT-proBNP as independent predictors of all-cause mortality. The area under the curve was 0.797 for the basic model including NT-proBNP, and the area under the curve comparing the overall model was 0.819, P = 0.016 (DeLong's test). Integrated discrimination improvement index after the inclusion of GDF-15 in the model with the mortality risk factors was 0.033; that is, the ability to predict death increased by 3.3% (P = 0.004). Net reclassification improvement was 0.548 (P < 0.001); that is, the capacity to improve the classification of the event (mortality) was 54.8%. GDF-15 concentrations were divided in tertiles (<1625, 1625-4330, and >4330 ng/L), and survival curves were evaluated using the Kaplan-Meier technique. Patients in the highest tertile had the poorest 5 year survival, at 16%, whereas the lowest tertile had the best survival, of 78% (P < 0.001). Conclusions: Growth differentiation factor 15 was superior to NT-proBNP for assessing prognosis in patients with HFpEF and HFmrEF. GDF-15 emerges as a strong, independent biomarker for identifying HFmrEF and HFpEF patients with worse prognosis.
Even warm climates get the shivers.

R. Kerr

DOI: https://doi.org/10.1126/SCIENCE.261.5119.292

IF: 56.9

1993-07-16

Science

Abstract:Researchers in the Greenland Ice-Core Project (GRIP) have found evidence of sharp climate shifts during the last two intergalcials. The Greenland ice sheet evidence shows that Greenland, over and over for decades to thousands of years, cooled drastically from temperatures equal to or higher than today's, often to virtual ice age conditions. The researchers believe that disruptions in the flow of warm water from the southern Atlantic to the North Atlantic, and the return flow of cold water to the south, may be linked to these climatic fluctuations. The present climate appears relatively stable, but that may change if temperatures warm due to increases in atmospheric greenhouse gases.
Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study

Lyu Lyu,Cui Xv,Juan Xu,Zhenzhen Liu,Yanru He,Wenjing Zhu,Lin Lin,Qiang Yang,Yun Wei,Jinda Wang,Taoke Huang,Benchuan Hao,Hongbin Liu

DOI: https://doi.org/10.1007/s11239-024-03019-5

Abstract:The prognostic value of growth differentiation factor-15 (GDF-15) in predicting long-term adverse outcomes in coronary heart disease (CHD) patients remains limited. Our study examines the association between GDF-15 and adverse outcomes over an extended period in CHD patients and firstly assesses the incremental prognostic effect of incorporating GDF-15 into the Framingham risk score (FRS)-based model. This single-center prospective cohort study included 3,321 patients with CHD categorized into 2,479 acute coronary syndrome (ACS) (74.6%) and 842 non-ACS (25.4%) groups. The median age was 61.0 years (range: 53.0-70.0), and 917 (27.6%) were females. Mortality and major adverse cardiovascular events (MACEs) included cardiovascular mortality, myocardial infarction (MI), stroke, and heart failure (HF) (inclusive of HF episodes requiring outpatient treatment and/or hospital admission). Cox regression models assessed the associations between GDF-15 and the incidence of all-cause mortality and MACEs. Patients were stratified into three groups based on GDF-15 levels: the first tertile group (< 1,370 ng/L), the second tertile group (1,370-2,556 ng/L), and the third tertile group (> 2,556 ng/L). The C-index, integrated discrimination improvement (IDI), net reclassification improvement (NRI), and decision curve analysis (DCA) were used to assess incremental value. Over a median 9.4-year follow-up, 759 patients (22.9%) died, and 1,291 (38.9%) experienced MACEs. The multivariate Cox model indicated that GDF-15 was significantly associated with all-cause mortality (per ln unit increase, HR = 1.49, 95% CI: 1.36-1.64) and MACEs (per ln unit increase, HR = 1.29, 95% CI: 1.20-1.38). These associations persisted when GDF-15 was analyzed as an ordinal variable (p for trend < 0.05). Subgroup analysis of ACS and non-ACS for the components of MACEs separately showed a significant association between GDF-15 and both cardiovascular mortality and HF, but no association was observed between GDF-15 and MI /stroke in both ACS and non-ACS patients. The addition of GDF-15 to the FRS-based model enhanced the discrimination for both all-cause mortality (∆ C-index = 0.009, 95% CI: 0.005-0.014; IDI = 0.030, 95% CI: 0.015-0.047; continuous NRI = 0.631, 95% CI: 0.569-0.652) and MACEs (∆ C-index = 0.009, 95% CI: 0.006-0.012; IDI = 0.026, 95% CI: 0.009-0.042; continuous NRI = 0.593, 95% CI: 0.478-0.682). DCA suggested that incorporating GDF-15 into the FRS-based model demonstrated higher net benefits compared to FRS-based models alone (All-cause mortality: FRS-based model: area under the curve of DCA (AUDC) = 0.0903, FRS-based model + GDF-15: AUDC = 0.0908; MACEs: FRS-based model: AUDC = 0.1806, FRS-based model + GDF-15: AUDC = 0.1833). GDF-15 significantly associates with the long-term prognosis of all-cause mortality and MACEs in CHD patients and significantly improves the prognostic accuracy of the FRS-based model for both outcomes.
Growth differentiation factor-15 and 5-years cardiovascular risk in chest pain patients presenting to the emergency department: a multicenter cohort study

L Crisanti,P Lopez-Ayala,J Boeddinghaus,L Koechlin,T Nestelberger,P Bima,J Glaeser,C Spagnuolo,O Miro,F J Martin Sanchez,M Christ,C Mueller

DOI: https://doi.org/10.1093/eurheartj/ehae666.1579

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Growth differentiation factor 15 (GDF-15) has been explored as a prognostic biomarker in multiple disease entities, including ischemic heart disease and heart failure (HF), but its role as a prognostic marker in chest pain patients presenting to the emergency department (ED) is unknown. Purpose To investigate the association between GDF-15 and 5-year all-cause mortality, cardiovascular mortality, and major adverse cardiac events (MACE), and to evaluate its prognostic incremental value. Methods Patients presenting to the ED with acute chest pain were prospectively enrolled in an international multicenter diagnostic study. GDF-15 concentrations were measured in a blinded fashion upon ED presentation. Follow-ups were performed at 3 months, 1-, 2- and 5-years. MACE was defined as the composite of cardiovascular mortality, acute myocardial infarction, stroke, and HF rehospitalization. Associations between GDF-15 and each prognostic outcome were modeled using multivariable Cox proportional hazard regression fitting restricted cubic splines to continuous variables. The magnitude of the effect of each GDF-15 unit change on multivariable-adjusted models was assessed graphically using dose-response plots. To compute an HR for the dose-response plots we chose a GDF-15 value of 1200 pg/mL as a reference value as this has been chosen in previous literature1. For the restricted cubic splines three knots were used. The added prognostic value of GDF-15 was evaluated by the increase in the C-statistic between a base and an extended model and the fraction of new information (FNI) provided by GDF-15. Results A total of 4779 chest pain patients had baseline GDF-15 values available. The median age was 61 [48-74] and 33% were female. Higher GDF-15 levels were more strongly associated with heart failure, kidney dysfunction, older age, hypertension, diabetes and coronary artery disease. GDF-15 was independently associated with 5-years all-cause mortality, cardiovascular mortality and MACE (Figure). When adding GDF-15 to a rich-for-prior-information base model which included age, sex, cardiovascular risk factors, creatinine, cardiac troponin and NT-proBNP, GDF-15 provided relevant incremental prognostic discrimination for 5-years all-cause death and cardiovascular death. (Table). Conclusions In chest pain patients presenting to the emergency department, GDF-15 concentration on admission was associated with 5-years all-cause mortality, cardiovascular mortality, and MACE. In addition, it provided relevant incremental prognostic information when added on top of troponin and NT-proBNP, the two current prognostic gold standard biomarkers.FigureTable

cardiac & cardiovascular systems
Sue daMones, the "911" Operator, and Boxer Shorts.

J. Jewell

DOI: https://doi.org/10.1542/hpeds.2011-0029

2012-04-01

Hospital Pediatrics

Abstract:Interacting with residents, medical students, and other “learners” (the new politically correct, nonperjorative term) affords loads of opportunities. Sure, this responsibility forces providers to maintain a certain level of competency; it reminds us of the fragility of the young ego; it allows us to believe that we are somehow molding the future of medicine. Working with learners also ensures loads of fodder for our story-telling and future comedy routines. Of course, non–health care personnel find none of these tales funny. In fact, most of our nonpediatric hospitalist colleagues find these stories juvenile and immature. But I think it is time we just admit it: pediatric hospitalists appreciate humor, especially humor involving our learners. Sometimes it gets us into trouble. Sometimes the hospital has to change its policies. Sometimes we just shake our heads and think, “Who is going to believe this?” The anonymous features inherent in overhead paging systems and beepers have the ability to draw pediatric residents from the darkness of midwinter depression into the light of midwinter dysthymia. Imagine wandering the halls, not sure which button to push on the elevator to get to the sixth floor, because the numbers all look like Asian characters after hours of sleep deprivation. (You will have difficulty with this imagery if your trained after-duty hours were mandated.) Suddenly, you hear a very earnest hospital operator instruct, “Billy Rubin, please report immediately to the Newborn Nursery. Billy Rubin to the nursery.” And you giggle in an elevator full of internists and psychiatrists until coffee is coming out of your nose. By the time you get to the sixth floor, Dr Laracy, the second-year pediatric resident, is at it again. This time, he requests the operator to recite the following, “Sue daMonas to microbiology. Sue daMonas to micro.” Or “Sal Monella to the …
Hepatocellular carcinoma incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up

G.P. Caviglia,S. Pelusi,A. Liguori,M. Guariglia,C. Rosso,A. Armandi,K. GJini,N. Viceconti,M.L. Abate,L. Miele,L. Valenti,E. Bugianesi

DOI: https://doi.org/10.1016/j.dld.2024.01.019

IF: 5.165

2024-02-01

Digestive and Liver Disease

Abstract:Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to become the leading cause of hepatocellular carcinoma (HCC) worldwide. The identification of novel tools able to stratify the risk of HCC is an unmet medical need. Aim To investigate the performance of non-invasive tests (NITs) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) for HCC risk stratification in MASLD patients on long-term follow-up (FU). Materials and Methods We retrospectively enrolled 366 MASLD patients (age: 58, 49–66 years; males: 198 [54.1%]; T2DM: 168, [45.9%]) with significant liver fibrosis (LSM≥8kPa or F≥2 at liver biopsy); 279 (76.2%) had compensated advanced chronic liver disease (cACLD) (LSM≥10kPa or F≥3 at liver biopsy). NITS (i.e. APRI, FIB-4, and NFS) were calculated at baseline. Serum PIVKA-II was measured by CLEIA (Lumipulse®G600II, Fujirebio). Results During 2.9 (IQR 1.0–4.3) years of FU, 19/366 (5.2%) patients developed HCC (1.49 per 100 person/years). Notably, all the 19 HCC occurred in cACLD patients (n=279) (2.06 per 100 person/years). Most patients had early-stage HCC (BCLC=0/A, n=14). In the whole cohort (n=366), NFS showed the best performance for HCC prediction (C-index=0.81), followed by FIB-4 (C-index=0.78), and by APRI (C-index=0.71); the accuracy of serum PIVKA-II was C-index=0.76. In patients with cACLD (n=279), the predictive performance of NITs was C-index=0.77 for NFS, C-index=0.75 for FIB-4, and C-index=0.68 for APRI, while PIVKA-II showed C-index=0.74. Remarkably, in cACLD patients the combination of NFS+PIVKA-II significantly improved the accuracy for HCC prediction (C-index=0.84), allowing patients to be stratified into 3 risk categories with different HCC incidence: low-risk (0/52; 0%), medium-risk (9/190; 4.7%), and high-risk (10/37; 27.0%) (p<0.001). Conclusion In MASLD patients with significant fibrosis, NFS showed appropriate performance for HCC prediction. However, in patients with more advanced liver disease, serum PIVKA-II may be a useful diagnostic complement to improve HCC prediction and risk stratification.

gastroenterology & hepatology
Non-invasive testing and risk-stratification in patients with MASLD

Mirko Zoncapè,Antonio Liguori,Emmanuel A. Tsochatzis

DOI: https://doi.org/10.1016/j.ejim.2024.01.013

IF: 7.749

2024-01-22

European Journal of Internal Medicine

Abstract:The development and validation of non-invasive fibrosis tests (NITs) has changed clinical practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most prevalent liver disease in western countries, with up to a third of the unselected adult population affected. In this article, we review the use of NITs in the diagnosis and staging of MASLD. We discuss their use in the diagnosis of steatosis, steatohepatitis and fibrosis and critically evaluate recently published data. These NITs include a variety of approaches, such as serum markers like FIB-4, pro-C3 and ELF, imaging techniques like Fibroscan® and MRE, and combined scores like Agile 3+ and Agile 4, offering a range of options for healthcare providers. Furthermore, these non-invasive tests also serve as valuable prognostic tools, allowing for better risk assessment and improved patient management, particularly in predicting liver-related events and overall mortality.

medicine, general & internal
Validation of serum non‐invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia

Karl Vaz,William Kemp,Ammar Majeed,John Lubel,Dianna J Magliano,Kristen M Glenister,Lisa Bourke,David Simmons,Stuart K Roberts

DOI: https://doi.org/10.1111/jgh.16774

2024-10-26

Journal of Gastroenterology and Hepatology

Abstract:Background and Aim The validity of non‐invasive tests (NITs) of liver fibrosis for the prediction of liver and mortality outcomes in an Australian cohort is unknown. We aimed to verify the utility of available NITs to predict overall and cause‐specific mortality and major adverse liver outcome (MALO). Methods This was an analysis from the Crossroads 1 clinic sub‐study of a randomly sampled adult cohort from regional Australia between 2001 and 2003. Baseline variables included demographic details, anthropometry, health and lifestyle data, and laboratory tests. Non‐alcoholic fatty liver disease (NAFLD) and metabolic‐(dysfunction) associated fatty liver disease (MAFLD) were defined by fatty liver index ≥ 60 and other accepted criteria. Outcomes were defined by the International Statistical Classification of Diseases and Related Health Problems 10th Revision codes for linked hospitalization and death registry data. Available serum‐based NITs were analyzed as predictors of overall, cardiovascular disease‐related, and cancer‐related mortality and MALO in those with fatty liver disease (FLD). Results In total, 1324 and 1444 participants were included for NAFLD and MAFLD analysis (prevalence 35.4% and 40.7%, respectively). There were 298 deaths (89 cardiovascular disease‐related and 98 cancer‐related) and 24 MALO over a median 19.7 years of follow‐up time. In both forms of FLD, fibrosis‐4 index, Steatosis‐Associated Fibrosis Estimator score, and Forns fibrosis score consistently had the highest area under the receiver operating characteristic curve (AUROC) for overall and cause‐specific mortality, with AUROC > 0.70 for each outcome. However, all had poor discriminatory ability for determining MALO in each FLD. Conclusions Several liver fibrosis NITs perform similarly reasonably well in predicting the risk of mortality outcomes in those with FLD but are poorly discriminatory for MALO prediction.

gastroenterology & hepatology
Membrane permeability of heavy water.

R. Rastogi,P. C. Skukla,B. Yadava

DOI: https://doi.org/10.1016/0005-2736(71)90122-2

1971-12-03

Biochimica et Biophysica Acta

Abstract:
291-OR: A Noninvasive Index for Significant Liver Fibrosis and Stratifying Risk of Cirrhosis in Patients with Type 2 Diabetes Mellitus in Primary Care

XIAOLONG QI,DONGFANG YOU,JIE SHEN,CHUAN LIU,YUPING CHEN,MING-HUA ZHENG,XIQIAO ZHOU,MINGXING HUANG,XUAN LIANG,TIANXURUN DENG,CHAO SUN,XIAO LIANG,HENG WAN,YAN WANG,YONGFEN ZHU,FANGFANG LV,TAOLONG T. ZHOU,SHANGHAO LIU,XIAOMEI WANG,XING LIU,RUILING HE,JIE LI,YANG ZHAO,VINCENT W. WONG

DOI: https://doi.org/10.2337/db24-291-or

IF: 7.7

2024-01-01

Diabetes

Abstract:Introduction & Objective: To propose a non-invasive index for detecting patients with T2DM at risk of significant liver fibrosis and cirrhosis in primary care. Methods: Five cohorts consist of 38,160 adults with T2DM were enrolled to develop and validate a non-invasive index for evaluating significant liver fibrosis and cirrhosis (Figure A). Results: Risk factors including Aspartate transaminase and boDy mass inDex were fitted to develop a test, termed the ADD index (available at: https://chess.nuist.edu.cn/consult/gzconsult/add_index). Using transient elastography (TE) as the reference, the ADD index performed better than FIB-4 and NFS for significant fibrosis (Figure B). A cutoff of 0 of the ADD index was selected to stratify patients into low- and high-risk group that should receive TE. AUC of the ADD index followed by TE was significantly higher than that of FIB-4 and NFS followed by TE (Figure B). Notably, using the ADD index combined with TE resulted in 11% cost savings compared to use TE alone. Compared with patients in low-risk group, those in high-risk group had a 2.90-fold (95% CI:1.44-5.82, P < 0.01) risk for cirrhosis (Figure C). Conclusions: The non-invasive ADD index can be applied to screen significant fibrosis and cirrhosis in patients with T2DM in primary care, and promoting those in high-risk group to further consult a hepatologist in secondary care. X. Qi: None. D. You: None. J. Shen: None. C. Liu: None. Y. Chen: None. M. Zheng: None. X. Zhou: None. M. Huang: None. X. Liang: None. T. Deng: None. C. Sun: None. X. Liang: None. H. Wan: None. Y. Wang: None. Y. Zhu: None. F. Lv: None. T.T. Zhou: None. S. Liu: None. X. Wang: None. X. Liu: None. R. He: None. J. Li: None. Y. Zhao: None. V.W. Wong: Consultant; AbbVie Inc., Boehringer-Ingelheim, Echosens, Gilead Sciences, Inc. Research Support; Gilead Sciences, Inc. Consultant; Intercept Pharmaceuticals, Inc., Inventiva Pharma, Novo Nordisk, Pfizer Inc., Sagimet Biosciences.
Comparison of blood-based liver fibrosis scores in the Mount Sinai Health System, MASLD Registry, and NHANES 2017-2020 study

Robert Chen,Ben Omega Petrazzini,Girish Nadkarni,Ghislain Rocheleau,Meena B Bansal,Ron Do

DOI: https://doi.org/10.1097/HC9.0000000000000515

2024-08-26

Abstract:Background: Liver fibrosis is a critical public health concern, necessitating early detection to prevent progression. This study evaluates the recently developed LiverRisk score and steatosis-associated Fibrosis Estimator (SAFE) score against established indices for prognostication and/or fibrosis prediction in 4diverse cohorts, including participants with metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: We used data from the Mount Sinai Data Warehouse (32,828 participants without liver disease diagnoses), the Mount Sinai MASLD/MASH Longitudinal Registry (422 participants with MASLD), and National Health and Nutrition Examination Survey 2017-2020 (4133 participants representing the general population) to compare LiverRisk score, FIB-4 index, APRI, and SAFE score. Analyses included Cox proportional hazards regressions, Kaplan-Meier estimates, and classification metrics to evaluate performance in prognostication and fibrosis prediction. Results: In Mount Sinai Data Warehouse, LiverRisk score was significantly associated with future liver-related outcomes but did not significantly outperform FIB-4 or APRI for predicting any of the outcomes. In the general population, LiverRisk score and SAFE score outperformed FIB-4 and APRI in identifying fibrosis, but LiverRisk score underperformed among participants who were non-White or had type 2 diabetes. Among participants with MASLD, SAFE score outperformed FIB-4 and APRI in 1 of 2 cohorts, but there were generally few significant performance differences between all 4 scores. Conclusions: LiverRisk score does not consistently outperform existing predictors in diverse populations, and further validation is needed before adoption in settings with significant differences from the original derivation cohorts. It remains necessary to replicate the ability of these scores to predict liver-specific mortality, as well as to develop diagnostic tools for liver fibrosis that are accessible and substantially better than current scores, especially among patients with MASLD and other chronic liver conditions.
[The role of growth differentiation factor-15 in assessing the prognosis of patients after uncomplicated myocardial infarction]

A S Galyavich,A A Sabirzyanova,L V Baleeva,Z M Galeeva

DOI: https://doi.org/10.18087/cardio.2023.2.n2152

2023-02-28

Kardiologiia

Abstract:Aim To study the role of growth differentiation factor 15 (GDF-15) in the long-term prognosis for patients after uncomplicated myocardial infarction (MI).Material and methods This study included 118 MI patients aged <70 years with and without ST-segment elevation on electrocardiogram (ECG). All patients underwent an examination that included ECG, echocardiography, Holter ECG monitoring, routine laboratory tests, and tests for plasma N-terminal pro-brain natriuretic peptide (NT-proBNT) and GDF-15. GDF-15 was measured by ELISA. The dynamics of patients was evaluated by interviews at 1, 3, 6, and 12 months. The endpoints were cardiovascular death and hospitalization for recurrent MI and/or unstable angina. Results Median concentration of GDF-15 in MI patients was 2.07 (1.55; 2.73) ng/ml. No significant dependence was found between GDF-15 concentration and age and gender, MI localization, smoking, body weight index, total cholesterol, and low-density lipoprotein cholesterol. During 12-month follow-up, 22.8 % of patients were hospitalized for unstable angina or recurrent MI. In 89.6 % of all cases of recurrent events, GDF-15 was ≥2.07 ng/ml. For patients with GDF-15 in the upper quartile, the time dependence of recurrent MI was logarithmic. High concentrations of NT-proBNP in MI patients were also associated with increased risk of cardiovascular death and recurrent cardiovascular events [RR, 3.3 (95 % CI, 1.87-5.96), р=0.046].Conclusion A combination of GDF-15 and NT-proBNP at high concentrations significantly reflects an adverse prognosis for patients with uncomplicated MI within 12 months [RR, 5.4 (95 % CI, 3.4-8.5), р=0.004].
Combined Use of GDF-15 and NT-Pro BNP for Outcome Prediction in Patients with Acute Heart Failure

Joanna Płonka,Anna Klus,Natalia Wężyk,Klaudia Dąbrowska,Lidia Rzepiela,Ewa Gawrylak-Dryja,Krzysztof Nalewajko,Piotr Feusette,Marek Gierlotka

DOI: https://doi.org/10.3390/jcm13195936

IF: 3.9

2024-10-05

Journal of Clinical Medicine

Abstract:Background: Acute heart failure (AHF) is characterized by a complex pathophysiology. Aims: This study aimed to evaluate the usefulness of combined serial measurements of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) and growth differentiation factor 15 (GDF-15) for predicting long-term outcomes in patients with AHF. Methods: This study included 104 consecutive patients hospitalized due to AHF. The mean (SD) age was 65 (±15) years. Blood samples were collected on admission, at discharge, and at a 30-day follow-up visit. The primary composite endpoint was all-cause mortality or rehospitalization due to heart failure (HF) at 1-year follow-up. Results: During follow-up, the primary endpoint occurred in 31 persons. In the ROC analysis, the optimal cut-off values of GDF-15 for predicting the outcome were 5115.5 pg/mL on admission, 4145 pg/mL at discharge, and 4218.5 pg/mL at the 30-day visit. For NT-pro BNP, the optimal cut-off reached 6011 ng/L, 1250 ng/L, and 1456.5 ng/L, respectively. Patients with both GDF-15 and NT-pro BNP levels above the cut-off value had a higher risk of the primary composite endpoint than patients with only one or none of the biomarkers elevated at three time points. At the 30-day visit, the model combining NT-pro BNP and GDF-15 showed the highest predictive value for the primary composite endpoint (area under the curve, 0.75). Conclusions: Combined serial measurements of NT-pro BNP and GDF-15 outperform single measurements in outcome prediction at 1-year follow-up in patients with AHF. The repetitive combined model may serve as a useful risk assessment tool and facilitate decision-making during long-term observation.

medicine, general & internal

[PULMONARY SYPHILIS IN PSEUDO-TUBERCULOTIC FORM (APROPOS OF A CASE SHOWING A RADIOLOGIC CURE)].

Monochromatic light sources in testing image intensifier tubes

Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.

Identification of Growth Differentiation Factor-15 as An Early Predictive Biomarker for Metabolic Dysfunction-Associated Steatohepatitis: A Nested Case-control Study of UK Biobank Proteomic Data

A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease

Elevated serum growth differentiation factor 15 and decorin predict the fibrotic progression of metabolic dysfunction-associated steatotic liver disease

Maf-5 Predicts Liver Fibrosis Risk And Outcome In The General Population With Metabolic Dysfunction

Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction

Even warm climates get the shivers.

Growth differentiation factor-15 predicts all-cause death and major adverse cardiovascular events in patients with coronary heart disease: a prospective cohort study

Growth differentiation factor-15 and 5-years cardiovascular risk in chest pain patients presenting to the emergency department: a multicenter cohort study

Sue daMones, the "911" Operator, and Boxer Shorts.

Hepatocellular carcinoma incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up

Non-invasive testing and risk-stratification in patients with MASLD

Validation of serum non‐invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia

Membrane permeability of heavy water.

291-OR: A Noninvasive Index for Significant Liver Fibrosis and Stratifying Risk of Cirrhosis in Patients with Type 2 Diabetes Mellitus in Primary Care

Comparison of blood-based liver fibrosis scores in the Mount Sinai Health System, MASLD Registry, and NHANES 2017-2020 study

[The role of growth differentiation factor-15 in assessing the prognosis of patients after uncomplicated myocardial infarction]

Combined Use of GDF-15 and NT-Pro BNP for Outcome Prediction in Patients with Acute Heart Failure